Related Experiment Video

Updated: Jul 16, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

Brian I Rini1

  • 1Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA. rinib2@ccf.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 24, 2007
PubMed

Insights

Targeting vascular endothelial growth factor (VEGF) with therapies like bevacizumab, sorafenib, and sunitinib shows promise for metastatic renal cell carcinoma. These agents offer clinical activity but require careful consideration of efficacy and toxicity.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Renal cell carcinoma (RCC) is a highly vascular malignancy.
  • Vascular endothelial growth factor (VEGF) is overexpressed in RCC, driving tumor growth.
  • VEGF-targeted therapies represent a novel therapeutic strategy for RCC.

Purpose of the Study:

  • To review VEGF-targeted therapies for metastatic renal cell carcinoma.
  • To explore the mechanisms of action, clinical efficacy, and toxicity of these agents.
  • To discuss future directions in VEGF-targeted therapy for RCC.

Main Methods:

  • Review of existing literature on VEGF-targeted agents in RCC.
  • Analysis of clinical trial data for bevacizumab, sorafenib, and sunitinib.
  • Exploration of preclinical and clinical data regarding combination therapies and sequencing.

Main Results:

  • Bevacizumab (anti-VEGF antibody), sorafenib, and sunitinib (VEGF receptor tyrosine kinase inhibitors) demonstrate clinical activity as monotherapy in metastatic RCC.
  • Each agent has a distinct efficacy and toxicity profile.
  • Combination regimens and strategic drug sequencing are under investigation.

Conclusions:

  • VEGF-targeted therapies are a significant advancement in metastatic renal cell carcinoma treatment.
  • Understanding individual agent profiles is crucial for patient management.
  • Future research should focus on optimizing treatment strategies through combination therapies and patient selection.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...